Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongbing Yang

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Journal of Virology|April 28, 2006
Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccineLucy Dorrell, Hongbing Yang, Beatrice Ondondo, et al.
Molecular Cancer Therapeutics|June 10, 2024
A Selective FGFR1/2 PROTAC Degrader with Antitumor ActivityYing Kong, Xinyue Zhao, Zhaofu Wang, et al.
Molecular Cancer Therapeutics|April 22, 2024
A selective Fibroblast Growth Factor Receptor 1/2 PROTAC degrader with antitumor activityYing Kong, Xinyue Zhao, Zhaofu Wang, et al.
Cell Reports|May 12, 2021
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8<sup>+</sup> T cell antiviral responsesHongbing Yang, Anuska Llano, Samandhy Cedeño, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 13, 2016
Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell ReceptorsHongbing Yang, Sandrine Buisson, Giovanna Bossi, et al.
Journal of the International AIDS Society|May 25, 2017
Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjectsGemma Hancock, Sara Morón-López, Jakub Kopycinski, et al.
Iscience|August 27, 2024
Deep learning-enhanced R-loop prediction provides mechanistic implications for repeat expansion diseasesJiyun Hu, Zetong Xing, Hongbing Yang, et al.
Plos Pathogens|February 28, 2015
Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responsesGemma Hancock, Hongbing Yang, Elisabeth Yorke, et al.
Science Immunology|March 26, 2021
HLA-E-restricted, Gag-specific CD8<sup>+</sup> T cells can suppress HIV-1 infection, offering vaccine opportunitiesHongbing Yang, Margarida Rei, Simon Brackenridge, et al.
European Journal of Immunology|October 16, 2015
Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cellsNicola Ternette, Hongbing Yang, Thomas Partridge, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Journal of Virology|April 28, 2006
Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccineLucy Dorrell, Hongbing Yang, Beatrice Ondondo, et al.
Molecular Cancer Therapeutics|June 10, 2024
A Selective FGFR1/2 PROTAC Degrader with Antitumor ActivityYing Kong, Xinyue Zhao, Zhaofu Wang, et al.
Molecular Cancer Therapeutics|April 22, 2024
A selective Fibroblast Growth Factor Receptor 1/2 PROTAC degrader with antitumor activityYing Kong, Xinyue Zhao, Zhaofu Wang, et al.
Cell Reports|May 12, 2021
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8<sup>+</sup> T cell antiviral responsesHongbing Yang, Anuska Llano, Samandhy Cedeño, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 13, 2016
Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell ReceptorsHongbing Yang, Sandrine Buisson, Giovanna Bossi, et al.
Journal of the International AIDS Society|May 25, 2017
Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjectsGemma Hancock, Sara Morón-López, Jakub Kopycinski, et al.
Iscience|August 27, 2024
Deep learning-enhanced R-loop prediction provides mechanistic implications for repeat expansion diseasesJiyun Hu, Zetong Xing, Hongbing Yang, et al.
Plos Pathogens|February 28, 2015
Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responsesGemma Hancock, Hongbing Yang, Elisabeth Yorke, et al.
Science Immunology|March 26, 2021
HLA-E-restricted, Gag-specific CD8<sup>+</sup> T cells can suppress HIV-1 infection, offering vaccine opportunitiesHongbing Yang, Margarida Rei, Simon Brackenridge, et al.
European Journal of Immunology|October 16, 2015
Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cellsNicola Ternette, Hongbing Yang, Thomas Partridge, et al.
Pageof 6